Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098673 | 0.88 | MAPT (0.52) | MAPTMEN1KMT2ATDP1HPGD | |
| SCHEMBL3862383 | 0.87 | MEN1 (0.50) | MAPTMEN1KMT2ATDP1HPGD | |
| SCHEMBL3862363 | 0.87 | MEN1 (0.50) | MAPTMEN1KMT2ATDP1HPGD | |
| SCHEMBL1951777 | 0.84 | MAPT (0.51) | MAPTMEN1KMT2ATDP1HPGD | |
| SCHEMBL1951779 | 0.84 | MAPT (0.51) | MAPTMEN1KMT2ATDP1HPGD | |
| SCHEMBL4143499 | 0.84 | MAPT (0.50) | MAPTMEN1KMT2ATDP1HPGD | |
| SCHEMBL4316365 | 0.84 | MAPT (0.50) | MAPTMEN1KMT2ATDP1HPGD | |
| SCHEMBL3873658 | 0.84 | ALDH1A1 (0.50) | MAPTMEN1KMT2ATDP1HPGD | |
| SCHEMBL4314418 | 0.83 | ADRA1A (0.49) | MAPTMEN1KMT2ATDP1HPGD | |
| SCHEMBL5361174 | 0.83 | ADRA1A (0.49) | MAPTMEN1KMT2ATDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765071-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-07-07 | — | — | US | disclosed |
| US-9328110-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| EP-1687307-B1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| EP-1687307-A4 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20070072893-A1 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-29 | — | — | US | disclosed |
| EP-1687307-A2 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M Innovative Properties Company (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051317-A2 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072893-A1 | Substituted imidazo ring systems and methods | IL2, IRF3, EIF2AK2 | MAPT 4775/4885MEN1 3421/4885KMT2A 4263/4885 |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | IL2, IRF3, EIF2AK2 | MAPT 4429/4885MEN1 3724/4885KMT2A 3717/4885 |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | IL2, IRF3, EIF2AK2 | MAPT 4429/4885MEN1 3724/4885KMT2A 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.